Coronavirus impact: Global Covid-19 deaths increases to 102,753

Moscow, Jul 13: Russia has become the first nation to complete clinical trials of a COVID-19 vaccine on humans. Chief researcher Elena Smolyarchuk, who heads the Center for Clinical Research on Medications at Sechenov University, told Russian news agency TASS on Sunday that the human trials for the vaccine have been completed at the university and the volunteers will be discharged soon.

"The research has been completed and it proved that the vaccine is safe. The volunteers will be discharged on July 15 and July 20," Smolyarchuk was quoted as saying in the report.

Though the results have been favourable with respect to the medication’s effectiveness, no further information was provided on when this vaccine would enter commercial production stage.

Russia had allowed clinical trials of two forms of a potential COVID-19 vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology on June 18.

The first vaccine, in the form of a solution for intramuscular administration, was carried out at the Burdenko Military Hospital.

Another vaccine, in the form of a powder for the preparation of a solution for intramuscular administration, was carried out at Sechenov First Moscow State Medical University.

The first stage of research on the vaccine at Sechenov University involved a group of 18 volunteers and the second group involved 20 volunteers.

After vaccination, all volunteers were expected to remain in isolation in a hospital for 28 days.

Earlier, results of the COVID-19 vaccine tests performed on a group of volunteers in Russia showed that they were developing immunity to the coronavirus.

"The data obtained by the Gamalei National Research Center for Epidemiology and Microbiology, proves that volunteers of the first and second groups are forming an immune response after injections of the vaccine against the coronavirus," according to an earlier statement from the Russian Defense Ministry.

Russia has reported 719,449 cases and 11,188 deaths to date.

There are at least 21 vaccines currently under key trials, according to the World Health Organisation (WHO).

The overall number of global COVID-19 cases crossed 12.9 million, while the deaths have increased to more than 5,69,000, according to Johns Hopkins University in the US.

As of Monday morning, the total number of cases stood at 1,29,10,357, while the fatalities rose to 5,69,128.

The US accounted for the world's highest number of infections at over 33 lakh. Brazil came in the second place with over 18 lakh infections. India is third worst affected with over 8.7 lakh people reported to have COVID-19.

Italian researchers have claimed that they have successfully developed a vaccine to contain coronavirus (COVID-19) which is likely to work on humans, a report said.

Luigi Aurisicchio, CEO of Takis, the firm developing the medication, said that a coronavirus candidate vaccine has neutralised the virus in human cells for the first time, the Arab News reported.

"This is the most advanced stage of testing of a candidate vaccine created in Italy. Human tests are expected after this summer," Aurisicchio was quoted as saying to Italian news agency ANSA.

"According to the Spallanzani Hospital, as far as we know we are the first in the world so far to have demonstrated neutralisation of the coronavirus by a vaccine. We expect this to happen in humans too," he added.

The researchers experimented with the vaccine on mice that had successfully developed antibodies that blocked the virus from infecting the cells. They further observed that the five vaccine candidates generated a large number of antibodies, and selected two with the best results.

All of the vaccine candidates currently being developed are based on the genetic material of DNA protein "spike", the molecular tip used by the coronavirus to enter human cells.

They are injected with the so-called "electroporation" technique, which consists of an intramuscular injection followed by a brief electrical impulse, helping the vaccine break into the cells and activating the immune system, the report said.

Researchers believe that this makes their vaccine particularly effective for generating functional antibodies against the "spike" protein, in particular in the lung cells, which are the most vulnerable to coronavirus.

"We are working hard for a vaccine coming from Italian research, with an all-Italian and innovative technology, tested in Italy and made available to everyone," Aurisicchio was quoted by the Arab News report.

"In order to reach this goal, we need the support of national and international institutions and partners who may help us speed up the process," he noted.

The total number of COVID-19 infections, fatalities and recoveries since the pandemic began has risen to 213,013 in the country.

Washington, Feb 25: Democratic presidential front-runner Senator Bernie Sanders on Monday slammed President Donald Trump for selling weapons to India, saying that the US should instead partner with New Delhi to fight climate change to save the planet.

Sanders, who has won the Nevada and New Hampshire primaries and tied in Iowa, made the comments after Trump, who is on a two-day visit to India, on Monday announced that the US will sign defence trade deals worth USD 3 billion with India.

In an address at a massive "Namaste Trump" rally at Motera stadium in Ahmedabad, Trump announced that deals to sell state-of-the-art military helicopters and other equipment worth over USD 3 billion will be sealed with India on Tuesday.

“Instead of selling USD 3 billion in weapons to enrich Raytheon, Boeing and Lockheed, the United States should be partnering with India to fight climate change,” Sanders said in a tweet, the first by a Democratic presidential candidate on Trump's India visit.

“We can work together to cut air pollution, create good renewable energy jobs, and save our planet,” he said.

However, a former White House official defended the US' decision to sell arms and weapons to India.

“I'm proud of my service in the White House, in which we poured enormous energy into deepening climate and green tech cooperation w/ India... and also advancing security cooperation and defense sales. I'd like to think both can be part of a strong, values-based partnership,” Joshua White said.

According to the US State Department, India plays a vital role in the US vision for a free and open Indo-Pacific.

In 2016, the US designated India as a Major Defence Partner. Commensurate with this designation, India in 2018 was granted Strategic Trade Authorization tier 1 status, which allows New Delhi to receive license-free access to a wide range of military and dual-use technologies that are regulated by the Department of Commerce.

Bilateral defence trade with India in a little over a decade has increased from near zero in 2008 to USD20 billion.

Among some of the key foreign military sales notified to Congress include MH-60R Seahawk helicopters (USD2.6 billion), Apache helicopters (USD2.3 billion), P-8I maritime patrol aircraft (USD3 billion), and M777 howitzers (USD737 million).

India was the first non-treaty partner to be offered a Missile Technology Control Regime Category-1 Unmanned Aerial System – the Sea Guardian UAS manufactured by General Atomics.

The State Department is also advocating for the Lockheed Martin F-21 and Boeing F/A-18 – two state of the art fighter aircraft that India is currently evaluating.

These platforms provide critical opportunities to enhance India's military capabilities and protect shared security interests in the Indo-Pacific region, it argued.

The top categories of DCS to India include aircraft, electronics and gas turbine engines.